Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus

Lupus

Volumn 10, Issue 3, 2001, Pages 135-139

  Ostensen M ^a   Villiger, P M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cox 1 inhibitors; Cox 2 inhibitors; Practice points; Side effects; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL FEATURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HEADACHE; HEALTH SURVEY; HUMAN; INFLAMMATION; KIDNEY DISEASE; LIVER TOXICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; MUSCULOSKELETAL DISEASE; NEPHROTIC SYNDROME; OVULATION; PALLIATIVE THERAPY; PREGNANCY; PRIORITY JOURNAL; REVIEW; SODIUM RETENTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0035050447     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120301668183556     Document Type: Review

References (34)

1. NSAID usage patterns by rheumatologists in the treatment of SLE
2. Morbidity and mortality in systemic lupus erythematosus during a 5 y period. A multicenter, prospective study of 1,000 patients
3. Basic biology and clinical application of cyclooxygenase-2 inhibitors
4. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis
5. A review of gastrointestinal manifestations of systemic lupus erythematosus
6. Do coclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
7. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function
8. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
9. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
10. Renal effects of indomethacin in patients with systemic lupus erythematosus
11. Renal syndromes associated with nonsteroidal anti-inflammatory drugs
12. Minimal change glomerulopathy associated with nonsteroidal anti-inflammatory drugs
13. Refractory nephrotic syndrome in lupus nephritis: Favorable response to indomethacin therapy
14. Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril
15. Cutaneous reactions to nonsteroidal anti-inflammatory drugs
16. Drug allergy in Chinese patients with systemic lupus erythematosus
17. An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs
18. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor
19. Mechanisms of adverse reactions in the skin from anti-rheumatic drugs
20. The spectrum of liver disease in systemic lupus erythematosus
21. Serious adverse reactions associated with sulindac
22. Effect of aspirin on liver tests in patients with RA or SLE and in normal volunteers
23. Salicylate hepatotoxicity in systemic lupus erythematosus: A common occurrence?
24. Hepatitis secondary to non steroid anti-inflammatory drugs
25. Cyclooxygenase systems in the mammalian brain
26. Central nervous system side effects of nonsteroidal anti-inflammatory drugs
27. Acute central nervous system symptoms caused by ibuprofen in connective tissue disease
28. Infertility may sometimes be associated with NSAID consumption
29. Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs
30. Treatment of inflammatory rheumatic disorders in pregnancy. What are the safest treatment options?
31. The management of thrombosis in the antiphospholipid-antibody syndrome
32. Thrombosis and ischemia in patients with systemic lupus erythematosus treated with celecoxib: A series of two cases
33. Interactions of non-steroidal anti-inflammatory drugs
34. Celecoxib, a specific Cox-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis